US Drug Recall Register

FDA Drug Recalls

14,450 recalls · Class II, newest first

Class II · Moderate risk Ongoing

Calcitriol Injection 1 mcg/mL

Reason CGMP Deviations: Firm went out of business and could no longer continue stability studies.

Akorn, Inc. D-0790-2023
Class II · Moderate risk Ongoing

Calcipotriene Topical Solution

Reason CGMP Deviations: Firm went out of business and could no longer continue stability studies.

Akorn, Inc. D-0789-2023
Class II · Moderate risk Ongoing

Ak-Poly-Bac

Reason CGMP Deviations: Firm went out of business and could no longer continue stability studies.

Akorn, Inc. D-0788-2023
Class II · Moderate risk Ongoing

Azelastine Hydrochloride Nasal Spray

Reason CGMP Deviations: Firm went out of business and could no longer continue stability studies.

Akorn, Inc. D-0787-2023
Class II · Moderate risk Ongoing

Artificial Tears Ointment

Reason CGMP Deviations: Firm went out of business and could no longer continue stability studies.

Akorn, Inc. D-0786-2023
Class II · Moderate risk Ongoing

Artificial Tears Solution

Reason CGMP Deviations: Firm went out of business and could no longer continue stability studies.

Akorn, Inc. D-0785-2023
Class II · Moderate risk Ongoing

Apraclonidine Ophthalmic Solution 0.5%

Reason CGMP Deviations: Firm went out of business and could no longer continue stability studies.

Akorn, Inc. D-0784-2023
Class II · Moderate risk Ongoing

Albuterol Sulfate Syrup

Reason CGMP Deviations: Firm went out of business and could no longer continue stability studies.

Akorn, Inc. D-0783-2023
Class II · Moderate risk Ongoing

Acyclovir Oral Suspension

Reason CGMP Deviations: Firm went out of business and could no longer continue stability studies.

Akorn, Inc. D-0782-2023
Class II · Moderate risk Ongoing

Acetic Acid Otic Solution

Reason CGMP Deviations: Firm went out of business and could no longer continue stability studies.

Akorn, Inc. D-0781-2023
Class II · Moderate risk Ongoing

Atropine Sulfate Ophthalmic Solution

Reason CGMP Deviations: Firm went out of business and could no longer continue stability studies.

Akorn, Inc. D-0779-2023
Class II · Moderate risk Completed

Calcitonin Salmon

Reason Presence of Foreign Substance: Glass splinter particle entrapped inside the pump ball seat rendered the pump inoperable.

Apotex Corp. NDC 60505-0823-6 D-0568-2023
Class II · Moderate risk Terminated

Fyremadel

Reason Presence of Particulate Matter: A piece of glass was found in a prefilled syringe.

Sun Pharmaceutical Industries Ltd. NDC 55566-1010-1 D-0569-2023
Class II · Moderate risk Ongoing

C-Semaglutide 5mg/mL injection

Reason Lack of assurance of sterility.

Pharmacy Plus, Inc. dba Vital Care Compounder D-0538-2023
Class II · Moderate risk Ongoing

Admelog

Reason Lack of Assurance of Sterility: Malformed crimped collar seal

Sanofi-Aventis U.S. LLC NDC 0024-5926-05 D-0575-2023
Class II · Moderate risk Completed

Pantoprazole sodium for Injection 40 mg*/vial

Reason CGMP Deviations; The impacted product and lot number was inadvertently placed into saleable inventory, which does not comply with approved procedures.

Methapharm Inc NDC 67850-150-10 D-0540-2023
Class II · Moderate risk Terminated

Simvastatin USP 40 mg

Reason CGMP deviations.

PD-Rx Pharmaceuticals, Inc. NDC 43063-0726-30 D-0561-2023
Class II · Moderate risk Terminated

Simvastatin USP 20 mg

Reason CGMP deviations.

PD-Rx Pharmaceuticals, Inc. NDC 43063-008-30 D-0560-2023
Class II · Moderate risk Terminated

Glimepiride USP

Reason CGMP deviations.

PD-Rx Pharmaceuticals, Inc. NDC 43063-0587-90 D-0559-2023
Class II · Moderate risk Terminated

Simvastatin USP

Reason CGMP deviations.

PD-Rx Pharmaceuticals, Inc. NDC 43063-0727-30 D-0558-2023
Class II · Moderate risk Terminated

Montelukast Sodium USP

Reason CGMP deviations.

PD-Rx Pharmaceuticals, Inc. NDC 43063-0762-30 D-0557-2023
Class II · Moderate risk Ongoing

Fast Acting Earwax Removal System

Reason CGMP Deviations: active ingredient may be subpotent before the labeled expiry due to degradation.

Pharma Nobis LLC D-0537-2023